We are live on ! Find out more
ELOX icon

Eloxx Pharmaceuticals

20 hedge funds and large institutions have $41.3M invested in Eloxx Pharmaceuticals in 2026 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

833% more capital inflows, than outflows

Capital inflows: $3.5M | Capital outflows: $375K

200% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 1

3.1% more ownership

Funds ownership: 63.8% → 66.9% (+3.1%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

9% less funds holding

Funds holding: 22 → 20 (-2)

40% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 5

Holders
20
Holders Change
-2
Holders Change %
-9.09%
% of All Funds
0.25%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
3
Increased
3
Reduced
1
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

ELOX Hedge Fund Activity: Q3 2026 in Review

20 of the 8,114 institutional investors tracked by Wall St. Rank reported a position in Eloxx Pharmaceuticals (ELOX) for Q3 2026, worth a combined $41.3M — up 19% from $34.7M a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of ELOX and 3 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 3 added.

The largest buyer was Morgan Stanley, adding an estimated $3.11M. The largest seller was Stonepine Capital Management, cutting an estimated $235K.

  • 20 institutional investors held Eloxx Pharmaceuticals (ELOX) as of Q3 2026, down from 22 in Q2 2026.
  • Funds reported $41.3M of Eloxx Pharmaceuticals stock for Q3 2026, up 19% quarter-over-quarter.
  • 3 funds opened new Eloxx Pharmaceuticals positions in Q3 2026 and 5 closed out, a net change of -2 holders.
  • The largest Eloxx Pharmaceuticals buyer in Q3 2026 was Morgan Stanley, an estimated $3.11M added.
  • The largest Eloxx Pharmaceuticals seller in Q3 2026 was Stonepine Capital Management, an estimated $235K sold.

Based on aggregated 13F filings for Q3 2026.